Since 1971, the US has led the world in funding cancer research and developing new treatments that have driven down death ...

A new study shows promising results for treating certain cancers with immunotherapy and completely avoiding surgery, ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

Some people with early-stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Following this standard treatment regimen, the rodents develop recurrent tumors, establishing what is referred to as an ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.